Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Johnson Chemical Pharmaceutical Works Co (ROCO:4747) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Johnson Chemical Pharmaceutical Works Co Receivables Turnover Related Terms
Johnson Chemical Pharmaceutical Works Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson Chemical Pharmaceutical Works Co Receivables Turnover Chart
Johnson Chemical Pharmaceutical Works Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Johnson Chemical Pharmaceutical Works Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Johnson Chemical Pharmaceutical Works Co Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Johnson Chemical Pharmaceutical Works Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Johnson Chemical Pharmaceutical Works Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson Chemical Pharmaceutical Works Co (ROCO:4747) has a Receivables Turnover of 1.41 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Johnson Chemical Pharmaceutical Works Co and its competitors. According to the industry distribution chart, Johnson Chemical Pharmaceutical Works Co ranks #384 out of 948 companies in the Drug Manufacturers industry, placing it in the top 40.5%.
Is Johnson Chemical Pharmaceutical Works Co's Receivables Turnover too high?
Johnson Chemical Pharmaceutical Works Co's current Receivables Turnover is 1.41. The Drug Manufacturers industry median Receivables Turnover is 5.07. Johnson Chemical Pharmaceutical Works Co's value of 1.41 is 72.2% below this industry median. Based on the distribution chart, Johnson Chemical Pharmaceutical Works Co ranks #384 out of 948 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Johnson Chemical Pharmaceutical Works Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Johnson Chemical Pharmaceutical Works Co's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Johnson Chemical Pharmaceutical Works Co ranks #384 out of 948 companies for Receivables Turnover. This puts Johnson Chemical Pharmaceutical Works Co in the upper half of its industry. The industry median Receivables Turnover is 5.07. Johnson Chemical Pharmaceutical Works Co's value of 1.41 is 72.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Johnson Chemical Pharmaceutical Works Co's current Receivables Turnover of 1.41 is 72.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Johnson Chemical Pharmaceutical Works Co and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Johnson Chemical Pharmaceutical Works Co's current Receivables Turnover is 1.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson Chemical Pharmaceutical Works Co stock overvalued right now?
Based on GuruFocus' analysis, Johnson Chemical Pharmaceutical Works Co (ROCO:4747) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$61.75, compared to a current price of NT$49.80 — trading 19.4% below its estimated fair value. The current Receivables Turnover is 1.41 and 72.2% below the Drug Manufacturers industry median of 5.07. Johnson Chemical Pharmaceutical Works Co's overall GF Score™ is 70/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Johnson Chemical Pharmaceutical Works Co (ROCO:4747), the current Receivables Turnover is 1.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Johnson Chemical Pharmaceutical Works Co (ROCO:4747) Overvalued in 2026?
Based on GuruFocus' analysis, Johnson Chemical Pharmaceutical Works Co stock appears to be undervalued.
The current stock price of NT$49.80 is trading 19.4% below its estimated GF Value™ of NT$61.75.
GuruFocus considers Johnson Chemical Pharmaceutical Works Co to be Modestly Undervalued.
Key valuation signals for ROCO:4747:
Receivables Turnover: 1.41
GF Value™: NT$61.75 vs. price of NT$49.80 (19.4% below fair value)
Industry Position: 72.2% below the Drug Manufacturers median (#384 of 948)
No single metric tells the full story. See the ROCO:4747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Johnson Chemical Pharmaceutical Works Co is engaged in the manufacturing of pharmaceutical ingredients, importing and selling pharmaceutical materials and products. It manufactures drugs in a variety of forms, including solid dosage forms, capsules (soft/hard), tablets (sugar/film-coated), powder and granule, as well as nasal sprays. It offers products in therapeutic areas including the central nervous system, respiratory, cardiovascular, gastrointestinal, and endocrine system, vitamins, anti-inflammatory, cough and cold, and pain relievers. Its revenue mainly comes from medical product sales.
70GF Score
Get the complete analysis for ROCO:4747
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4747 has been successfully added to your 
